Some include the discovery of the basis of amniocentesis and new fertility treatments; the founding of two leading treatments for Multiple Sclerosis (MS) called Copaxone® and Rebif®; and the development of advanced image scanning technology. Currently under development are vaccines for flu and diabetes; growing new organs and T cells to treat damaged spines from stem cells; and finding out how diseases originated. Discovering how medicine and therapies will evolve is also a key focus: personalised medicine that provides treatments and therapies based on the individual’s genetic make-up are the future, and Weizmann’s new Nancy and Stephen Grand Israel National Center for Personalized Medicine is working hard to make this a reality. In Australia, Weizmann collaborations with leading universities have also played a role in understanding the basis of disease in a bid to develop better treatments and help our world to become a healthier place. Weizmann has recently joined forces with Australia’s famous Garvan Institute of Medical Research to establish the Garvan-Weizmann Centre for Cellular Genomics where these two great research centres will create synergistic research platforms to advance cellular genomic science.
Leading MS drugs Copaxone® and Rebif® developed by Weizmann, treating some of the 23,700 Australians with MS
A type 1 (juvenile) diabetes treatment is now in Phase III clinical trials
Deciphered 3-billion-base-pair genome in its role as part of the Human Genome Project
Weizmann Scientists – led by Professor Dan Tawfik – have designed artificial enzymes that can evolve in a test tube at faster rates, opening doors for different applications in medicine and industry.
The cause of brain damage from injury is from glutamate, a neurotransmitter that floods the brain when such an event occurs. A method the makes this excess glutamate leave the brain quickly and safely into the blood stream has been developed by Weizmann’s Professor Vivian Teichberg.
Now used around the world, the process of performing a uterine biopsy before in vitro fertilization was found by Weizmann’s Professor Nava Dekel to double the chance of pregnancy success.
A new Weizmann Institute of Science approach promises to advance cancer immunotherapy by increasing the proliferation rate of cancer-targeting immune cells while retaining their ability to kill cancer cells. Cellular…
New research at the Weizmann Institute of Science has resulted in a new miniature genetic circuit that could lead to the next phase in bio-nanotechnology and artificial cell design. Weizmann…
Weizmann Insitute scientists have mapped common types of brain tumours at unprecedented resolution – and identified a possible reason why some patients fail to respond to a new drug. The…
Weizmann Institute of Science researchers have found how the multiple sclerosis drug – Copaxone – protects the heart muscle and improves its function after a heart attack. In the late…
Weizmann’s research into advanced technology is immense and acts as a time line for technology’s evolution.
Nearly half the life science research at the Weizmann Institute of Science in Israel is focussed on cancer.
Although over the centuries we have learned much about our physical world, from the earth below to the stars above, there are still many mysteries to uncover.
Providing solutions to our planet’s environmental challenges is part of Weizmann’s business.
Science education is a core endeavour of the Weizmann Institute of Science.